Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.46 |
| ▸ | HTR6 | P50406 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403231 | 0.90 | MTNR1B (0.42) | QDPRMTNR1BHTR6DRD3CHRNA7 | |
| SCHEMBL6409562 | 0.87 | SLC6A2 (0.50) | MTNR1BDRD3 | |
| SCHEMBL6404493 | 0.85 | CYP2D6 (0.42) | MTNR1BDRD3 | |
| SCHEMBL6001636 | 0.80 | DRD2 (0.52) | MTNR1BDRD3 | |
| SCHEMBL6002172 | 0.80 | OPRM1 (0.51) | MTNR1BDRD3CNR1CNR2 | |
| SCHEMBL6406991 | 0.80 | MTNR1B (0.47) | MTNR1BCHRNA7CNR1CNR2 | |
| SCHEMBL6405341 | 0.80 | MTNR1B (0.50) | MTNR1BDRD3 | |
| SCHEMBL6000179 | 0.80 | MTNR1B (0.45) | MTNR1BCHRNA7CNR1CNR2 | |
| SCHEMBL6405935 | 0.79 | EPHX2 (0.46) | MTNR1BCNR1CNR2 | |
| SCHEMBL22411195 | 0.79 | EPHX2 (0.46) | MTNR1BCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | claimed |
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
| WO-2005113527-A1 | TETRAHYDRONAPHTHYL- PIPERAZINES AS 5-HT1B ANTAGONISTS, INVERSE AGONISTS AND PARTIAL AGONISTS | PFIZER PRODUCTS INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288304-A1 | Tetrahydronaphthylpiperazines as 5HT1B antagonists, inverse agonists and partial agonists | HTR1A, HTR1B, HTR1D | QDPR 288/4885MTNR1B 63/4885HTR6 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.